Home Products Most Popular Contact
No items in your cart.

Detection and Management of Preeclampsia: Current Laboratory Testing and Emerging Biomarkers (Online CE Course)

(based on 148 customer ratings)

Author: David J. Moffa, PhD
Reviewer: Jenny Camele, MT(ASCP)

Preeclampsia (PE) is a multisystem, transient disorder of pregnancy, which affects 5-10% of pregnant women (usually during their first pregnancy). This course defines preeclampsia (PE) and discusses its prevalence, characteristics, signs, and symptoms. Pathophysiology, causes, treatment, and prevention are presented in this course along with the laboratory tests used in the diagnosis of preeclampsia.

See all available courses »

Continuing Education Credits

P.A.C.E.® Contact Hours (acceptable for AMT, ASCP, and state recertification): 2 hour(s)
Course number 578-031-20, approved through 4/30/2022
Florida Board of Clinical Laboratory Personnel Credit Hours - General (Clinical Chemistry/UA/Toxicology): 2 hour(s)
Course number 20-773632, approved through 9/1/2020

Objectives

  • Define preeclampsia (PE) and discuss its prevalence, characteristics, signs, and symptoms.
  • Identify the characteristics of mild and severe PE as well as the relationship to the HELLP Syndrome.
  • Define the risk factors for PE and differentiate between eclampsia and the HELLP Syndrome.
  • Describe the pathophysiology of PE, its cause, treatment, and prevention.
  • Describe the main triggers used to diagnose PE.
  • Identify laboratory tests used to assist in the diagnosis of PE.
  • Define and describe angiogenesis relative to its possible role in PE and associated pro-angiogenic and anti-angiogenic factors.
  • Describe the various potential biomarkers for identifying pregnant women at risk for PE.
  • Identify assay methods available for several potential biomarkers.

Customer Ratings

(based on 148 customer ratings)

Course Outline

Click on the links below to preview selected pages from this course.
  • Background and Overview of Preeclampsia
      • Background and Overview
      • Which of the following statements is NOT true in describing preeclampsia (PE)?
      • Preeclampsia (PE) affects 5-10% of pregnant women and typically occurs after 20 weeks' gestation.
  • Classification and Characteristics of Preeclampsia
      • Classification and Characteristics of Preeclampsia (PE)
      • HELLP Syndrome
      • Which of the following can be defined as the presence of hypertension (blood pressure >= 140/90) on two occasions at least six hours apart, but wit...
      • What condition NOT attributable to any other disorder is associated with eclampsia?
      • Which statement is TRUE regarding the HELLP syndrome?
  • Risk Factors for Preeclampsia
      • Risk Factors for Preeclampsia (PE)
      • Which of the following are considered risk factors for PE?
  • Pathophysiology of Preeclampsia
  • Treatment and Prevention
      • Treatment and Management of Preeclampsia (PE)
      • Treatment and Management of PE, continued
      • Treatment and Prevention (Aspirin Usage)
      • Postpartum PE
      • True or false? The only cure for PE is delivery of the baby.
      • Which statement is true regarding the use of aspirin to prevent PE?
  • Current Laboratory Testing Used for PE Workup
  • Emerging Biomarkers for Preeclampsia
      • Emerging Biomarkers to Identify Risk for Preeclampsia (PE)
      • Angiogenesis and Angiogenic Biomarkers
      • Table I: Circulating Levels of Angiogenic Biomarkers in Preeclampsia (PE)
      • Table II: Circulating Levels of Other Potential Biomarkers in Preeclampsia (PE).
      • Laboratory Methods for Quantitation of Biomarkers Used for Determining Risk of PE
      • Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels.
      • What statements are TRUE concerning angiogenesis and angiogenic biomarkers?
      • PIGF acts as a vasodilator increasing the diameter of existing arteries, and its serum levels have been found to be significantly lower in mild and se...
      • Choose the correct answer regards the circulating levels of sFlt-1, sEng, and the sFlt-1/PIGF ratio in pregnant women with preeclampsia (PE).
      • Which potential preeclampsia (PE) biomarker that is decreased in PE can be described as a glycoprotein, which is derived from the trophoblast cells an...
      • Which potential PE biomarker is a cell surface molecule expressed by platelets and endothelial cells and circulating levels are increased in PE?
  • Summary and Conclusions
  • References
      • References

Additional Information

Level of instruction: Intermediate

Intended Audience: Medical laboratory scientists, medical technologists, and technicians. This course is also appropriate for medical laboratory science students and pathology residents.

Author information: David Moffa, PhD, has over 30 years of experience in the health care industry as an executive manager, clinical laboratory director, and medical laboratory scientist. He is currently a technical consultant for Kentmere Healthcare, Wilmington, DE, and until his retirement, was the Regional Director for LabCorp, Inc. He holds a PhD in medical biochemistry from the School of Medicine, West Virginia University.

Reviewer information: Prior to her retirement in 2012, Jenny Camele was employed by Laboratory Corporation of America as the manager of customer service operations for the Fairmont West Virginia Region and a Quality Assurance committee member. She holds a Bachelor of Science degree in Medical Technology from West Virginia University.

burr cells arrows
elisa
indirect Elisa final
question polychromatophilic RBCs
sandwich ELISA
schistocytes arrows
question sickle cells
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 129 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart


burr cells arrows


elisa


indirect Elisa final


question polychromatophilic RBCs


sandwich ELISA


schistocytes arrows


question sickle cells